KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Operating Margin (2018 - 2025)

Castle Biosciences' Operating Margin history spans 7 years, with the latest figure at 4.4% for Q4 2025.

  • For Q4 2025, Operating Margin fell 909.0% year-over-year to 4.4%; the TTM value through Dec 2025 reached 12.44%, down 1505.0%, while the annual FY2025 figure was 12.44%, 1505.0% down from the prior year.
  • Operating Margin for Q4 2025 was 4.4% at Castle Biosciences, up from 8.19% in the prior quarter.
  • Across five years, Operating Margin topped out at 5.92% in Q3 2024 and bottomed at 91.3% in Q1 2022.
  • The 5-year median for Operating Margin is 17.23% (2023), against an average of 28.53%.
  • The largest annual shift saw Operating Margin crashed -7252bps in 2022 before it soared 6749bps in 2024.
  • A 5-year view of Operating Margin shows it stood at 60.59% in 2021, then rose by 2bps to 59.55% in 2022, then soared by 86bps to 8.56% in 2023, then skyrocketed by 155bps to 4.69% in 2024, then tumbled by -194bps to 4.4% in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Operating Margin are 4.4% (Q4 2025), 8.19% (Q3 2025), and 4.93% (Q2 2025).